生血宝合剂对吉西他滨联合顺铂化疗发生的骨髓抑制患者的疗效观察

Effect of Shengxuebao mixture on patients with myelosuppression caused by Gemcitabine combined with Cisplatin chemotherapy

目的探讨生血宝合剂在吉西他滨联合顺铂(GP)化疗发生骨髓抑制患者中的效果。方法选取2019年7月至2020年7月本院收治的92例恶性肿瘤患者,按随机数字表法分为对照组(46例),观察组(46例)。对照组予以GP化疗方案,21 d为1周期,共化疗4个周期,观察组加用生血宝合剂,连续用药14 d。对比2组近期疗效、血常规指标、骨髓抑制程度、不良反应。结果2组近期有效率(RR)相当,差异无统计学意义(P>0.05);治疗前,2组血红蛋白(Hb)、白细胞相比,差异无统计学意义(P>0.05);治疗后,观察组Hb、白细胞高于对照组,骨髓抑制程度轻于对照组,差异有统计学意义(P<0.05);2组不良反应比较,差异无统计学意义(P>0.05)。结论生血宝合剂能够改善GP化疗发生骨髓抑制患者的血常规指标,减轻骨髓抑制程度,且无严重不良反应,安全可行。

Objective To investigate the effect of Shengxuebao mixture in patients with myelosuppression caused by Gemcitabine combined with Cisplatin(GP)chemotherapy.Methods A total of 92 malignant tumor patients admitted to our hospital from July 2019 to July 2020 were selected and divided into control group(46 cases)and observation group(46 cases)according to the random number table method.The patients in control group were given GP chemotherapy regimen,21 days for 1 cycle,a total of 4 cycles′chemotherapy,while the ones in observation group were given Shengxuebao mixture continuously for 14 days.The short-term efficacy rate(RR),blood routine indicators,bone marrow suppression,and adverse reactions were compared between the two groups.Results The difference of the RR between the two groups was not statistically significant(P>0.05).There was no statistically significant difference between the two groups′hemoglobin(Hb)and white blood cell(WBC)before treatment(P>0.05).After treatment,the Hb and WBC of the observation group were higher than those of the control group,and the degree of bone marrow suppression was lighter than that of the control group.The difference was statistically significant(P<0.05).The adverse reactions of the two groups were similar,and the difference was not statistically significant(P>0.05).Conclusion Shengxuebao Mixture can improve the blood routine indexes of patients with myelosuppression caused by GP chemotherapy,reduce the degree of myelosuppression,without serious adverse reactions,and is security and feasibility.